References
- Okamoto I, Morita S, Tashiro N, Imamura F, Inoue A, Seto T, Yamamoto
N, Ohe Y, Nakagawa K, Fukuoka M. Real world treatment and outcomes in
EGFR mutation-positive non-small cell lung cancer: Long-term follow-up
of a large patient cohort. Lung Cancer . 2018;117:14-19.
- Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A,
Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K,
Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024
Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive
Non-Small-Cell Lung Cancer. N Engl J Med .
2016;375(19):1823-1833.
- Husain AN, Colby TV, Ordóñez NG, Allen TC, Attanoos RL, Beasley MB,
Butnor KJ, Chirieac LR, Churg AM, Dacic S, Galateau-Sallé F, Gibbs A,
Gown AM, Krausz T, Litzky LA, Marchevsky A, Nicholson AG, Roggli VL,
Sharma AK, Travis WD, Walts AE, Wick MR, Guidelines for Pathologic
Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus
Statement From the International Mesothelioma Interest Group.Arch Pathol Lab Med . 2018;142(1):89-108.
- Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P,
Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W,
Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. PARAMOUNT:
Final overall survival results of the phaseⅢ study of maintenance
pemetrexed versus placebo immediately after induction treatment with
pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung
cancer. J Clin Oncol . 2013;31(23):2895-2902.
- Pujol JL, Paz-Ares L, de Marinis F, Dediu M, Thomas M, Bidoli P,
Corral J, San Antonio B, Chouaki N, John W, Zimmermann A,
Visseren-Grul C, Gridelli C. Long-term and low-grade safety results of
a phase III study (PARAMOUNT): maintenance pemetrexed plus best
supportive care versus placebo plus best supportive care immediately
after induction treatment with pemetrexed plus cisplatin for advanced
nonsquamous non-small-cell lung cancer. Clin Lung Cancer .
2014;15(6):418-425.
- Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J,
Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS,
Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F,
Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin
plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive
patients with advanced-stage non-small-cell lung cancer. J Clin
Oncol . 2008;26(21):3543-3551.
- Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P,
Simms L, Shepherd FA. The differential efficacy of pemetrexed
according to NSCLC histology: a review of two Phase III studies.Oncologist . 2009;14(3):253-263.
- Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie
P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P.
Phase III study of pemetrexed in combination with cisplatin versus
cisplatin alone in patients with malignant pleural mesothelioma.J Clin Oncol . 2003;21(14):2636-2644.
- Tada A, Sakaguchi K, Kobayashi M, Kagoshima T, Yamazaki Y, Kamisawa O.
A case of adenocarcinoma of the lung with malignant pleural effusion
in elderly patient treated effectively by pemetrexed and carboplatin.
(in Japanese.). Gan To Kagaku Ryoho . 2012;39(3):425-427.
- Takeda T, Itano H, Fukita S, Saitoh M, Takeda S. Long progression-free
survival by pemetrexed continuation maintenance therapy following
cisplatin-based chemotherapy in malignant pleural mesothelioma.Intern. Med . 2014;53(20):2347-2351.
- Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, Yu CJ, Yang PC.
Thymidylate synthase and dihydrofolate reductase expression in
non-small cell lung carcinoma: the association with treatment efficacy
of pemetrexed. Lung Cancer . 2011;74(1):132-138.
- Sun JM, Han J, Ahn JS, Park K, Ahn MJ. Significance of thymidylate
synthase and thyroid transcription factor 1 expression in patients
with nonsquamous non-small cell lung cancer treated with
pemetrexed-based chemotherapy. J Thorac Oncol .
2011;6(8):1392-1399.
- Ozasa H, Oguri T, Uemura T, Miyazaki M, Maeno K, Sato S, Ueda R.
Significance of thymidylate synthase for resistance to pemetrexed in
lung cancer. Cancer Sci . 2010;101(1):161-166.
- Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse
B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O’Byrne KJ, Moro-Sibilot
D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A,
Wilner KD, Jänne PA. Crizotinib versus chemotherapy in advanced
ALK-positive lung cancer. N Engl J Med . 2013;368(25):2385-2394.